Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911
Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...